The Renoprotective Effects of RAS Inhibition: Focus on Prevention and Treatment of Chronic Kidney Disease

References

• . National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43( suppl 1):S1–S290
   PubMed Web of Science ®Google Scholar
• . Sarnak MJ, Levey AS, Schoolwerth AC, ; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiolgy, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–1065
   PubMed Web of Science ®Google Scholar
• . Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 suppl 1):S117–S131
   PubMed Web of Science ®Google Scholar
• . Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49( suppl 2):S1–S180
   PubMed Web of Science ®Google Scholar
• . Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005;18(4 pt 2):95S–99S
   Web of Science ®Google Scholar
• . Kopyt NP. Slowing progression along the renal disease continuum. J Am Osteopath Assoc. 2005;105(4):207–215
   PubMedGoogle Scholar
• . Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002;39(2 pt 2):316–322
   PubMed Web of Science ®Google Scholar
• . Siragy HM, de Gasparo M, El-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension. 2001;38(2):183–186
   PubMed Web of Science ®Google Scholar
• . Ha H, Kim KH. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res Clin Pract. 1999;45(2–3):147–151
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–1462
   PubMed Web of Science ®Google Scholar
• . Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577–581
   PubMed Web of Science ®Google Scholar
• . Sano T, Hotta N, Kawamura T, . Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med. 1996;13(2):120–124
   PubMed Web of Science ®Google Scholar
• . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Fassi A, Ilieva AP, ; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951
   PubMed Web of Science ®Google Scholar
• . Agodoa LY, Appel L, Bakris GL, ; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–2728
   PubMed Web of Science ®Google Scholar
• . Wright JT Jr, Bakris G, Greene T, ; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Perna A, Loriga G, ; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939–946
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VAL sartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672–678
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D, ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR, ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Makino H, Haneda M, Babazono T, . The telmisartan renoprotective study from incipient nephropathy to overt nephropathy—rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res. 2005;33(6):677–686
   PubMed Web of Science ®Google Scholar
• . Makino H, Haneda M, Babazono T, ; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–1578
   PubMed Web of Science ®Google Scholar
• . Hollenberg NK, Parving HH, Viberti G, . Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921–1926
   PubMed Web of Science ®Google Scholar
• . Weir MR, Hollenberg NK, Daley WL, . Dose-related antihypertensive effects of valsartan therapy in African American patients with type 2 diabetes: the Diovan Reduction Of Proteinuria (DROP) study. Abstract P-446 MP-4. J Clin Hypertens (Greenwich). 2007;9( suppl A):A186
   Google Scholar
• . Mogensen CE, Neldam S, Tikkanen I, . Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–1444
   PubMed Web of Science ®Google Scholar
• . Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361(9352):117–124
   PubMed Web of Science ®Google Scholar
• . Li PK-T, Leung CB, Chow KM, ; HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751–760
   PubMed Web of Science ®Google Scholar
• . Jafar TH, Schmid CH, Landa M, . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient level data. Ann Intern Med. 2001;135:73–87
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting—enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153
   PubMed Web of Science ®Google Scholar
• . Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(4 suppl 2):S90–S97
   Web of Science ®Google Scholar
• . Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23( suppl 2):B54–B64
   PubMed Web of Science ®Google Scholar
• . Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol. 2002;13( suppl 3):S165–S168
   PubMed Web of Science ®Google Scholar
• . Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2(3):581–590
   PubMed Web of Science ®Google Scholar
• . Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30(6):1351–1356
   PubMed Web of Science ®Google Scholar
• . Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens. 2006;19(12):1241–1248
   PubMed Web of Science ®Google Scholar
• . Fogari R, Derosa G, Zoppi A, . Effect of telmisartan—amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007;20(4):417–422
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Bain SC, Bouter P, ; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–1961
   PubMed Web of Science ®Google Scholar
• . Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368(9545):1449–1456
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Casas JP, Chua W, Loukogeorgakis S, . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–2033
   PubMed Web of Science ®Google Scholar
• . Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68( suppl 99):S57–S65
   Web of Science ®Google Scholar
• . Ibsen H, Olsen MH, Wachtell K, . Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension study. Hypertension. 2005;45(2):198–202
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Remuzzi G, Parving HH, . Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921–927
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Remuzzi G, Parving HH, . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320
   PubMed Web of Science ®Google Scholar
• . Douglas JG, Bakris GL, Epstein M, ; Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525–541
   PubMedGoogle Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30( suppl 1):S4–S41
   PubMedGoogle Scholar
• . , ONTARGET InvestigatorsYusuf S, Teo KK, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Imai E, Ito S, Haneda M, Chan JCN, Makino H; ORIENT Investigators. Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): rationale and study design. Hypertens Res. 2006;29(9):703–709
   PubMed Web of Science ®Google Scholar
• . Maione A, Nicolucci A, Craig JC, ; LIRICO study group. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol. 2007;20(6):646–655
   PubMed Web of Science ®Google Scholar
• . Pozzi C, Del Vecchio L, Casartelli D, . ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J Nephrol. 2006;19(4):508–514
   PubMed Web of Science ®Google Scholar
• . Haller H, Viberti GC, Mimran A, . Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403–408
   PubMed Web of Science ®Google Scholar